Last reviewed · How we verify
NCT06311396
Development of a Neuronal Microscope
NA trial testing genetic model in Hepatic Carcinoma in 30 participants. Completed in 1 January 2025.
1 January 2024
Quick facts
| Lead sponsor | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 30 |
| Start date | 1 January 2021 |
| Primary completion | 1 January 2024 |
| Estimated completion | 1 January 2025 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- genetic model
Conditions studied
- Hepatic Carcinoma — all drugs for Hepatic Carcinoma →
Sponsor
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Who can join
18 and older, any sex, with Hepatic Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and is a leading cause of cancer-related death worldwide. The prognosis of HCC remains poor, with a 5-year survival rate of 18%. Risk factors for HCC include viral infection, autoimmune hepatitis, chronic alcohol use or metabolic fatty liver disease, obesity, and diabetes mellitus.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06311396
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hepatic Carcinoma
Currently open trials in the same condition.
- NCT07359586 — Laryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia · recruiting
- NCT06342414 — An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer · recruiting
- NCT04220944 — Combined Locoregional Treatment With Immunotherapy for Unresectable HCC. · Phase 1 · active not recruiting
Other Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico trials
Trials by the same sponsor.
- NCT07492433 — Risk Factors, Incidence, and Clinical Impact of Intraluminal Thrombosis Following FET and TEVAR · not yet recruiting
- NCT07402174 — EIT- Guided Lung Recruitment in pARDS · NA · not yet recruiting
- NCT07234097 — The Influence of Music on perceiVed paIn and leVels of Anxiety whiLe unDergoing transperIneal Prostate Biopsy: the VIVAL · NA · not yet recruiting
- NCT07317193 — DEFINING THE GENETIC DRIVERS OF ADULT-ONSET CHOLESTATIC LIVER DISEASE · NA · recruiting
- NCT07487961 — Assess Abdominal Aortic Diameter in Females · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06311396 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
- Last refreshed: 27 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06311396.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing